Agios Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Agios Pharmaceuticals, Inc.
The European Medicines Agency is this week deciding whether its reviews of planned marketing applications from Rocket Pharmaceuticals and Servier merit accelerated assessment status.
Several small biopharmas are launching new drugs independently, sales of some of those drugs appear to be off to a slow start.
The targeted therapy won approval for myelodysplastic syndrome patients with IDH1 mutations, who have a higher propensity for progression to acute myeloid leukemia.
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.